HALO vs. BIIB, INCY, UTHR, NBIX, EXEL, BMRN, EXAS, RGEN, MDGL, and IONS
Should you be buying Halozyme Therapeutics stock or one of its competitors? The main competitors of Halozyme Therapeutics include Biogen (BIIB), Incyte (INCY), United Therapeutics (UTHR), Neurocrine Biosciences (NBIX), Exelixis (EXEL), BioMarin Pharmaceutical (BMRN), Exact Sciences (EXAS), Repligen (RGEN), Madrigal Pharmaceuticals (MDGL), and Ionis Pharmaceuticals (IONS). These companies are all part of the "biotechnology" industry.
Halozyme Therapeutics vs. Its Competitors
Halozyme Therapeutics (NASDAQ:HALO) and Biogen (NASDAQ:BIIB) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their media sentiment, risk, earnings, institutional ownership, dividends, analyst recommendations, valuation and profitability.
97.8% of Halozyme Therapeutics shares are held by institutional investors. Comparatively, 87.9% of Biogen shares are held by institutional investors. 2.9% of Halozyme Therapeutics shares are held by insiders. Comparatively, 0.2% of Biogen shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
In the previous week, Biogen had 2 more articles in the media than Halozyme Therapeutics. MarketBeat recorded 14 mentions for Biogen and 12 mentions for Halozyme Therapeutics. Biogen's average media sentiment score of 0.69 beat Halozyme Therapeutics' score of 0.41 indicating that Biogen is being referred to more favorably in the news media.
Biogen has higher revenue and earnings than Halozyme Therapeutics. Biogen is trading at a lower price-to-earnings ratio than Halozyme Therapeutics, indicating that it is currently the more affordable of the two stocks.
Halozyme Therapeutics currently has a consensus price target of $61.90, suggesting a potential upside of 14.52%. Biogen has a consensus price target of $188.48, suggesting a potential upside of 42.12%. Given Biogen's stronger consensus rating and higher probable upside, analysts plainly believe Biogen is more favorable than Halozyme Therapeutics.
Halozyme Therapeutics has a net margin of 44.76% compared to Biogen's net margin of 15.07%. Halozyme Therapeutics' return on equity of 136.91% beat Biogen's return on equity.
Halozyme Therapeutics has a beta of 1.15, indicating that its stock price is 15% more volatile than the S&P 500. Comparatively, Biogen has a beta of 0.14, indicating that its stock price is 86% less volatile than the S&P 500.
Summary
Halozyme Therapeutics and Biogen tied by winning 8 of the 16 factors compared between the two stocks.
Get Halozyme Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for HALO and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding HALO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Halozyme Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:HALO) was last updated on 7/7/2025 by MarketBeat.com Staff
